Analysts at Merriman Curhan Ford made positive comments on Regeneron Pharmaceuticals (Nasdaq: REGN) following this morning's better-than-expected Q2 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE